Literature DB >> 17410470

Defining normalcy of the somatotropic axis: an attainable goal?

Ariel L Barkan1.   

Abstract

The diagnoses of acromegaly and dwarfism require biochemical confirmation of abnormal GH and IGF-1 concentrations. The same parameters are used for therapeutic decisions, i.e. initiation or termination of particular treatments. Therefore, reliable and epidemiologically and statistically proven criteria of normalcy for GH and IGF-1 are required for these tasks to be accomplished. Despite major progress in all these areas, the definition of what constitutes "normalcy" of the somatotropic axis is still lacking. Using an example of acromegaly, we discuss the contradictions and the uncertainties of the biochemical diagnosis of this disease.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17410470     DOI： 10.1007/s11102-007-0029-7

Source DB:  PubMed          Journal:  Pituitary        ISSN： 1386-341X            Impact factor:   3.599


  30 in total

1.  Radiotherapy in acromegaly: the argument against.

Authors:  Ariel L Barkan
Journal:  Clin Endocrinol (Oxf)       Date:  2003-02       Impact factor: 3.478

2.  IMMUNOASSAY OF HUMAN GROWTH HORMONE IN PLASMA.

Authors:  S M GLICK; J ROTH; R S YALOW; S A BERSON
Journal:  Nature       Date:  1963-08-24       Impact factor: 49.962

Review 3.  [Acromegaly in elderly people].

Authors:  R Desailloud; S Crépin-Hemon; B Simovic-Corroyer
Journal:  Ann Endocrinol (Paris)       Date:  2005-12       Impact factor: 2.478

4.  Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria.

Authors:  Cristina L Ronchi; Virginia Varca; Claudia Giavoli; Paolo Epaminonda; Paolo Beck-Peccoz; Anna Spada; Maura Arosio
Journal:  J Clin Endocrinol Metab       Date:  2004-12-07       Impact factor: 5.958

5.  Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly.

Authors:  P J Jenkins; P Bates; M N Carson; P M Stewart; J A H Wass
Journal:  J Clin Endocrinol Metab       Date:  2006-01-10       Impact factor: 5.958

Review 6.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

7.  An audit of outcome of treatment in acromegaly.

Authors:  A S Bates; W Van't Hoff; J M Jones; R N Clayton
Journal:  Q J Med       Date:  1993-05

8.  Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.

Authors:  Pamela U Freda; Abu T Nuruzzaman; Carlos M Reyes; Robert E Sundeen; Kalmon D Post
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

9.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

Authors:  B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

10.  A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue.

Authors:  J L Walker; P A Crock; S N Behncken; S W Rowlinson; L M Nicholson; T J Boulton; M J Waters
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958
View more
  3 in total

1.  Reference ranges for an automated chemiluminescent assay for serum insulin-like growth factor I (IGF-I) in a large population of healthy adults from Buenos Aires.

Authors:  M Guitelman; F Smithuis; N Garcia Basavilbaso; C Aranda; B Fabre; A Oneto
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

2.  Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients.

Authors:  Laura Boero; Marcos Manavela; Karina Danilowicz; Analia Alfieri; Maria Carolina Ballarino; Alberto Chervin; Natalia García-Basavilbaso; Mariela Glerean; Mirtha Guitelman; Monica Graciela Loto; Jose Alberto Nahmías; Amelia Susana Rogozinski; Marisa Servidio; Nicolas Marcelo Vitale; Débora Katz; Patricia Fainstein Day; Graciela Stalldecker; Maria Susana Mallea-Gil
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

3.  Insulin-like growth factor I and the pathogenesis of delirium: a review of current evidence.

Authors:  Dimitrios Adamis; David Meagher
Journal:  J Aging Res       Date:  2011-07-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.